Abstract 177P
Background
Stomach cancer (SC) ranks as the 3rd leading cause of death among all cancer-related fatalities in the South Asia (SA) region. The complex interplay of cultural, lifestyle, and demographic factors in SA compounds the challenge to public health posed by the significant burden of stomach cancer.
Methods
Using the Global Burden of Disease framework, this study examined deaths and disability-adjusted life years (DALYs) attributed to SC caused by smoking by age, sex, and year across the 5 countries of the SA region from 1990-2019. Additionally, projections for the number of deaths up to 2040 were derived through regression analysis.
Results
The total count of deaths attributed to SC due to smoking witnessed an increase from 6,948 (95%UI: 4,963-8,890) in 1990 to 9,353 (95%UI: 6,632-12,325) in 2019. Concurrently, DALYs rose from 177,675 (95%UI: 124,165-232,327) in 1990 to 222,290 (95%UI: 149,831-299,787) in 2019. Assessing the annual percentage of change (APC), the Age-Standardized Mortality Rate (ASMR) experienced a decline of 49% from 1990-2019. Among the SA countries, Nepal exhibited the highest APC increase in total deaths at 76%, followed by Bhutan at 73%, India at 40%, Pakistan at 20%, and Bangladesh at 13% from 1990-2019. Conversely, the APC increase in DALYs was greatest in Nepal at 51%, while Bangladesh reported the lowest increase at 3% during the same period. Notably, the age group of 65-69 years recorded the highest number of deaths (1,555), while the age group of 60-64 years experienced the highest DALYs (37,194) in 2019. In terms of gender disparities, males bore a higher burden of stomach cancer attributable to smoking compared to females over the past three decades. The study's projections indicate an estimated 3,952 deaths (95%UI: 2,036-6,347) by the year 2040.
Conclusions
While notable advancements have been made in the management of SC, the burden attributed to smoking continues to rise over the last 3 decades. This accounts for 9.44% of deaths among the overall causes of SC-related fatalities. It emphasizes the importance of comprehensive tobacco control strategies to mitigate this burden, considering the diverse social, economic, and cultural factors unique to the region.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract